Annual Report

Overview

The report highlights VivaGel® BV launches across the UK, Europe, Asia and New Zealand and progress of three internal DEP® products into phase 2 trials. It describes rapid development of an SPL7013 COVID-19 nasal spray following activity against SARS-CoV-2. The report also introduces Starpharma's first standalone ESG disclosure, covering products and patient health, people, governance and the environment, with workforce and board diversity information.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2020
Period: 1 July 2019 – 30 June 2020
Publication date: 27 August 2020
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services